- Report
- August 2024
- 265 Pages
Global
From €5631EUR$6,360USD£4,925GBP
€7039EUR$7,950USD£6,156GBP
- Report
- November 2023
- 163 Pages
Global
From €2214EUR$2,500USD£1,936GBP
- Report
- November 2023
- 163 Pages
Asia Pacific
From €1328EUR$1,500USD£1,161GBP
- Report
- November 2023
- 164 Pages
Middle East, Africa
From €1328EUR$1,500USD£1,161GBP
- Report
- April 2023
- 326 Pages
Global
From €3188EUR$3,600USD£2,788GBP
- Report
- February 2022
- 185 Pages
Global
From €3188EUR$3,600USD£2,788GBP
- Report
- July 2023
- 147 Pages
Africa, Middle East
From €1328EUR$1,500USD£1,161GBP
- Report
- December 2025
- 150 Pages
Germany
From €3409EUR$3,850USD£2,981GBP
- Report
- November 2025
- 150 Pages
India
From €3409EUR$3,850USD£2,981GBP
- Report
- November 2025
- 150 Pages
China
From €3409EUR$3,850USD£2,981GBP
- Report
- September 2024
- 150 Pages
Global
From €3409EUR$3,850USD£2,981GBP
€4294EUR$4,850USD£3,755GBP
- Report
- September 2024
- 150 Pages
Global
From €3409EUR$3,850USD£2,981GBP
€4294EUR$4,850USD£3,755GBP
- Report
- August 2024
- 150 Pages
Global
From €2470EUR$2,789USD£2,160GBP
- Report
- August 2024
- 150 Pages
Global
From €2470EUR$2,789USD£2,160GBP
- Report
- August 2024
- 150 Pages
Global
From €2470EUR$2,789USD£2,160GBP
- Report
- August 2024
- 200 Pages
Global
From €3426EUR$3,869USD£2,996GBP
- Report
- May 2024
- 160 Pages
Global
From €4400EUR$4,969USD£3,848GBP
- Report
- May 2024
- 140 Pages
Global
From €4382EUR$4,949USD£3,832GBP
- Report
- September 2023
- 160 Pages
Global
From €3187EUR$3,599USD£2,787GBP
- Report
- July 2023
- 140 Pages
Global
From €4382EUR$4,949USD£3,832GBP

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer.
The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more